Clinical Trial Update: This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety, pharmacokinetics, and antiviral response of Boehringer Ingelheim compounds BI-207127 and BI-201335 in patients with chronic hep…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• BI 201335
• BI 207127 (BI-207127)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Hepatitis C, Chronic | Phase 2 | Status: COMPLETED | Results posted: 2016-04-13